4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Other Accumulated Expenses of $200000.0 for Q1 2026, up 24.22% year-over-year from $161000.0 in Q1 2025, and up 55.04% on a QoQ basis from $129000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) has 8 years of Other Accumulated Expenses data on file, last reported at $200000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 24.22% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (up 24.22% YoY) and the FY2025 annual result came in at $129000.0, up 13.16% from the prior year.
- Other Accumulated Expenses climbed to $200000.0 in Q1 2026 per FDMT's latest filing, from $129000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $748000.0 in Q2 2022 and bottomed at $45000.0 in Q1 2023.
- The 5-year median for Other Accumulated Expenses is $129000.0 (2025), against an average of $180411.8.
- The widest annual swing landed in 2023, when Other Accumulated Expenses plunged 93.18%; it then surged 215.56% in 2024.
- Tracing FDMT's Other Accumulated Expenses over 5 years: stood at $382000.0 in 2022, then plunged by 72.77% to $104000.0 in 2023, then rose by 9.62% to $114000.0 in 2024, then increased by 13.16% to $129000.0 in 2025, then surged by 55.04% to $200000.0 in 2026.
- Per Business Quant, the three latest FDMT Other Accumulated Expenses figures stand at $200000.0 (Q1 2026), $129000.0 (Q4 2025), and $108000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | 4D Molecular Therapeutics | 674.52 Mn | 674.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 142,000.00 |
| Dec 31, 2023 | 104,000.00 |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 382,000.00 |
| Sep 30, 2022 | 188,000.00 |
| Jun 30, 2022 | 748,000.00 |
| Mar 31, 2022 | 209,000.00 |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 420,000.00 |
| Jun 30, 2021 | 356,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 491,000.00 |
| Dec 31, 2019 | 481,000.00 |